Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 77,600 shares, a drop of 37.2% from the August 31st total of 123,500 shares. Based on an average trading volume of 690,300 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.2% of the shares of the stock are short sold. Currently, 5.2% of the shares of the stock are short sold. Based on an average trading volume of 690,300 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a report on Saturday, September 27th. Wall Street Zen lowered Avalon GloboCare to a “strong sell” rating in a research note on Saturday, September 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Avalon GloboCare Price Performance

Avalon GloboCare stock opened at $2.34 on Tuesday. The stock has a market capitalization of $8.99 million, a P/E ratio of -0.12 and a beta of 0.03. Avalon GloboCare has a 12-month low of $1.87 and a 12-month high of $11.66. The firm’s 50-day moving average is $2.32 and its two-hundred day moving average is $3.08.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.